...Solasia Pharma K.K. (Tokyo:4597) said China's National Medical Products Administration approved Episil (SP-03) to relieve pain... ...relieve pain associated with oral mucositis. The company added ¥50 (31%) to ¥210 on Thursday. Episil... ...Camurus was off SEK2 to SEK67.30 on Thursday. Lee's added HK$0.05 to HK$6.46.
Hongjiang Li
episil (SP-03, episil oral spray)
Camurus...
...Solasia Pharma K.K. (Tokyo:4597) said China's National Medical Products Administration approved Episil (SP-03) to relieve pain... ...pain associated with oral mucositis. The company added ¥50 (31%) to ¥210 on Feb. 21. Episil... ...Kong, China Solasia Pharma K.K. (Tokyo:4597), Tokyo, Japan Product: Episil (SP-03) Business: Neurology
Hongjiang Li
episil (SP-03, episil oral spray)
Camurus...
The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
...Solasia Pharma K.K. (Tokyo:4597) said Japan's Ministry of Health, Labour and Welfare (MHLW) approved Episil (SP-03... ...cancer patients. Solasia's partner Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) has Japanese rights to Episil... ...FluidCrystal film. It is marketed in the U.S. and Europe. Solasia has exclusive rights to Episil...
...commercialization rights in Europe for Episil oral spray to Camurus. Sinclair, which gained European commercialization rights for Episil... ...rights that it sublicensed to Teva under a 2011 deal. Teva has rights to commercialize Episil... ...the return but that it will incur a non-cash impairment charge of £950,000 ($1.5 million). Episil...
